Methylation of the neutral endopeptidase gene promoter in human prostate cancers

Badar A. Usmani, Ruoqian Shen, Michael Janeczko, Christos N. Papandreou, Wen-Hsiang Lee, William G. Nelson, Joel B. Nelson, David M. Nanus

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors implicated in the growth of androgen-independent prostate cancer (PC). Decreased NEP expression in hormone-refractory metastatic PCs can result from hormonal therapies because NEP transcription is induced by androgens and down-regulated by androgen withdrawal. NEP is encoded by a gene that contains a 5' CpG island spanning a transcriptional regulatory region. In this study, we investigate whether DNA hypermethylation of the NEP promoter accompanies decreased NEP expression in PC cell lines and whether it occurs in human PC tissues in vivo. DNA isolated from PC cell lines and from normal and neoplastic human prostate tissues was restriction-digested with a methylation-sensitive restriction endonuclease and analyzed by Southern blot using a 5' sequence-specific NEP probe. Methylation-specific PCR was performed using PCR primers designed to discriminate between methylated and unmethylated alleles, and reverse transcription-PCR using NEP-specific primers was performed on cDNA extracted from PC cells treated with 5-aza-2'- deoxycytidine. Methylation of the NEP promoter was present in androgen- independent PC cell lines but not in androgen-dependent or small-cell derived PC cell lines and in 3 of 21 (14%) primary PCs from patients with androgen- dependent disease. Exposure of PC cells to the demethylating agent 5-aza-2'- deoxycytidine led to an increase in NEP transcripts in DU-145 and PC-3 cells. These data show that hypermethylation of the 5' CpG NEP island is associated with a loss of NEP expression in PC. Loss of NEP expression via hypermethylation of the NEP promoter may contribute to the development of neuropeptide-stimulated PCs.

Original languageEnglish (US)
Pages (from-to)1664-1670
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number5
StatePublished - May 1 2000
Externally publishedYes

Fingerprint

Neprilysin
Methylation
Prostatic Neoplasms
Genes
Androgens
decitabine
Cell Line
Neuropeptides
Polymerase Chain Reaction
CpG Islands
Nucleic Acid Regulatory Sequences
DNA
DNA Restriction Enzymes
Southern Blotting
Islands
Reverse Transcription

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Usmani, B. A., Shen, R., Janeczko, M., Papandreou, C. N., Lee, W-H., Nelson, W. G., ... Nanus, D. M. (2000). Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clinical Cancer Research, 6(5), 1664-1670.

Methylation of the neutral endopeptidase gene promoter in human prostate cancers. / Usmani, Badar A.; Shen, Ruoqian; Janeczko, Michael; Papandreou, Christos N.; Lee, Wen-Hsiang; Nelson, William G.; Nelson, Joel B.; Nanus, David M.

In: Clinical Cancer Research, Vol. 6, No. 5, 01.05.2000, p. 1664-1670.

Research output: Contribution to journalArticle

Usmani, BA, Shen, R, Janeczko, M, Papandreou, CN, Lee, W-H, Nelson, WG, Nelson, JB & Nanus, DM 2000, 'Methylation of the neutral endopeptidase gene promoter in human prostate cancers', Clinical Cancer Research, vol. 6, no. 5, pp. 1664-1670.
Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee W-H, Nelson WG et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clinical Cancer Research. 2000 May 1;6(5):1664-1670.
Usmani, Badar A. ; Shen, Ruoqian ; Janeczko, Michael ; Papandreou, Christos N. ; Lee, Wen-Hsiang ; Nelson, William G. ; Nelson, Joel B. ; Nanus, David M. / Methylation of the neutral endopeptidase gene promoter in human prostate cancers. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 5. pp. 1664-1670.
@article{752ce06b6303410d89ba816b1bb45663,
title = "Methylation of the neutral endopeptidase gene promoter in human prostate cancers",
abstract = "Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors implicated in the growth of androgen-independent prostate cancer (PC). Decreased NEP expression in hormone-refractory metastatic PCs can result from hormonal therapies because NEP transcription is induced by androgens and down-regulated by androgen withdrawal. NEP is encoded by a gene that contains a 5' CpG island spanning a transcriptional regulatory region. In this study, we investigate whether DNA hypermethylation of the NEP promoter accompanies decreased NEP expression in PC cell lines and whether it occurs in human PC tissues in vivo. DNA isolated from PC cell lines and from normal and neoplastic human prostate tissues was restriction-digested with a methylation-sensitive restriction endonuclease and analyzed by Southern blot using a 5' sequence-specific NEP probe. Methylation-specific PCR was performed using PCR primers designed to discriminate between methylated and unmethylated alleles, and reverse transcription-PCR using NEP-specific primers was performed on cDNA extracted from PC cells treated with 5-aza-2'- deoxycytidine. Methylation of the NEP promoter was present in androgen- independent PC cell lines but not in androgen-dependent or small-cell derived PC cell lines and in 3 of 21 (14{\%}) primary PCs from patients with androgen- dependent disease. Exposure of PC cells to the demethylating agent 5-aza-2'- deoxycytidine led to an increase in NEP transcripts in DU-145 and PC-3 cells. These data show that hypermethylation of the 5' CpG NEP island is associated with a loss of NEP expression in PC. Loss of NEP expression via hypermethylation of the NEP promoter may contribute to the development of neuropeptide-stimulated PCs.",
author = "Usmani, {Badar A.} and Ruoqian Shen and Michael Janeczko and Papandreou, {Christos N.} and Wen-Hsiang Lee and Nelson, {William G.} and Nelson, {Joel B.} and Nanus, {David M.}",
year = "2000",
month = "5",
day = "1",
language = "English (US)",
volume = "6",
pages = "1664--1670",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Methylation of the neutral endopeptidase gene promoter in human prostate cancers

AU - Usmani, Badar A.

AU - Shen, Ruoqian

AU - Janeczko, Michael

AU - Papandreou, Christos N.

AU - Lee, Wen-Hsiang

AU - Nelson, William G.

AU - Nelson, Joel B.

AU - Nanus, David M.

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors implicated in the growth of androgen-independent prostate cancer (PC). Decreased NEP expression in hormone-refractory metastatic PCs can result from hormonal therapies because NEP transcription is induced by androgens and down-regulated by androgen withdrawal. NEP is encoded by a gene that contains a 5' CpG island spanning a transcriptional regulatory region. In this study, we investigate whether DNA hypermethylation of the NEP promoter accompanies decreased NEP expression in PC cell lines and whether it occurs in human PC tissues in vivo. DNA isolated from PC cell lines and from normal and neoplastic human prostate tissues was restriction-digested with a methylation-sensitive restriction endonuclease and analyzed by Southern blot using a 5' sequence-specific NEP probe. Methylation-specific PCR was performed using PCR primers designed to discriminate between methylated and unmethylated alleles, and reverse transcription-PCR using NEP-specific primers was performed on cDNA extracted from PC cells treated with 5-aza-2'- deoxycytidine. Methylation of the NEP promoter was present in androgen- independent PC cell lines but not in androgen-dependent or small-cell derived PC cell lines and in 3 of 21 (14%) primary PCs from patients with androgen- dependent disease. Exposure of PC cells to the demethylating agent 5-aza-2'- deoxycytidine led to an increase in NEP transcripts in DU-145 and PC-3 cells. These data show that hypermethylation of the 5' CpG NEP island is associated with a loss of NEP expression in PC. Loss of NEP expression via hypermethylation of the NEP promoter may contribute to the development of neuropeptide-stimulated PCs.

AB - Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors implicated in the growth of androgen-independent prostate cancer (PC). Decreased NEP expression in hormone-refractory metastatic PCs can result from hormonal therapies because NEP transcription is induced by androgens and down-regulated by androgen withdrawal. NEP is encoded by a gene that contains a 5' CpG island spanning a transcriptional regulatory region. In this study, we investigate whether DNA hypermethylation of the NEP promoter accompanies decreased NEP expression in PC cell lines and whether it occurs in human PC tissues in vivo. DNA isolated from PC cell lines and from normal and neoplastic human prostate tissues was restriction-digested with a methylation-sensitive restriction endonuclease and analyzed by Southern blot using a 5' sequence-specific NEP probe. Methylation-specific PCR was performed using PCR primers designed to discriminate between methylated and unmethylated alleles, and reverse transcription-PCR using NEP-specific primers was performed on cDNA extracted from PC cells treated with 5-aza-2'- deoxycytidine. Methylation of the NEP promoter was present in androgen- independent PC cell lines but not in androgen-dependent or small-cell derived PC cell lines and in 3 of 21 (14%) primary PCs from patients with androgen- dependent disease. Exposure of PC cells to the demethylating agent 5-aza-2'- deoxycytidine led to an increase in NEP transcripts in DU-145 and PC-3 cells. These data show that hypermethylation of the 5' CpG NEP island is associated with a loss of NEP expression in PC. Loss of NEP expression via hypermethylation of the NEP promoter may contribute to the development of neuropeptide-stimulated PCs.

UR - http://www.scopus.com/inward/record.url?scp=0034075990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034075990&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1664

EP - 1670

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -